Albireo Pharma Inc Est. EPS Q/Q
What is the Est. EPS Q/Q of Albireo Pharma Inc?
The Est. EPS Q/Q of Albireo Pharma Inc is -136.55%
What is the definition of Est. EPS Q/Q?
Prospective quarterly EPS growth rate, year over year, is the estimated increase of the company’s EPS for the current quarter compared to performance from a past corresponding quarter.
= current quarter yoy (year over year)
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Est. EPS Q/Q of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with est. eps q/q similar to Albireo Pharma Inc
- Cypress Environmental Partners L.P has Est. EPS Q/Q of -139.13%
- Mercury General has Est. EPS Q/Q of -139.06%
- Natura &Co S.A has Est. EPS Q/Q of -137.50%
- Richardson Electronics has Est. EPS Q/Q of -137.50%
- Tactile Systems Technology Inc has Est. EPS Q/Q of -136.84%
- HudBay Minerals has Est. EPS Q/Q of -136.84%
- Albireo Pharma Inc has Est. EPS Q/Q of -136.55%
- Newpark Resources has Est. EPS Q/Q of -136.36%
- Vitru Ltd has Est. EPS Q/Q of -136.36%
- Big Lots Inc has Est. EPS Q/Q of -136.00%
- Travelzoo has Est. EPS Q/Q of -136.00%
- New York City REIT has Est. EPS Q/Q of -135.85%
- Oil States International has Est. EPS Q/Q of -135.71%